Research Program - Experimental Therapeutics

研究计划 - 实验治疗学

• 批准号: 10400657
• 负责人: Giuseppe Giaccone
• 金额: $ 8.25万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-08-15 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10400657
• 关键词: Address; Adolescent and Young Adult; Adoptive Cell Transfers; Applications Grants; Area; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Catchment Area; Clinic; Clinical; Clinical Drug Development; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Comprehensive Cancer Center; Contracts; County; Data Science; Development; Direct Costs; Disease; District of Columbia; Doctor of Philosophy; Funding; Future; Grant; Guidelines; Health; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hospitals; Immune system; Immunotherapy; Institution; Investigational Therapies; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Meridians; Mission; Molecular; NCI Center for Cancer Research; National Cancer Institute; Nature; Neoplasm Metastasis; New Jersey; Oncology; Paper; Pathway interactions; Patients; Pediatric Hematology; Peer Review; Pharmaceutical Preparations; Phase I Clinical Trials; Prognosis; Prognostic Marker; Publishing; Research; Research Personnel; Resistance; Resource Sharing; Role; Science; Services; Strategic Planning; Stromal Neoplasm; Structure; Surrogate Markers; Therapeutic; Thymic Carcinoma; Translational Research; Underserved Population; Universities; Washington; Work; base; cancer biomarkers; cancer care; cancer diagnosis; cancer prevention; circulating biomarkers; health disparity; immune resistance; instrumentation; investigator-initiated trial; liquid crystal polymer; malignant breast neoplasm; meetings; member; minority health disparity; molecular oncology; nano-string; next generation sequencing; optimal treatments; pembrolizumab; personalized immunotherapy; pre-clinical; pre-clinical research; precision medicine; precision oncology; predictive marker; programs; survivorship; trend; tumor microenvironment; tumor progression; underserved minority; Address; Adolescent and Young Adult; Adoptive Cell Transfers; Applications Grants; Area; Cancer Burden; Cancer Center; Cancer Center Support Grant; Cancer Control; Cancer Survivorship; Catchment Area; Clinic; Clinical; Clinical Drug Development; Clinical Research; Clinical Trials; Clinical Trials Design; Collaborations; Comprehensive Cancer Center; Contracts; County; Data Science; Development; Direct Costs; Disease; District of Columbia; Doctor of Philosophy; Funding; Future; Grant; Guidelines; Health; Hematologic Neoplasms; Hematopoietic Stem Cell Transplantation; Hospitals; Immune system; Immunotherapy; Institution; Investigational Therapies; Leadership; Malignant Neoplasms; Malignant neoplasm of lung; Malignant neoplasm of pancreas; Meridians; Mission; Molecular; NCI Center for Cancer Research; National Cancer Institute; Nature; Neoplasm Metastasis; New Jersey; Oncology; Paper; Pathway interactions; Patients; Pediatric Hematology; Peer Review; Pharmaceutical Preparations; Phase I Clinical Trials; Prognosis; Prognostic Marker; Publishing; Research; Research Personnel; Resistance; Resource Sharing; Role; Science; Services; Strategic Planning; Stromal Neoplasm; Structure; Surrogate Markers; Therapeutic; Thymic Carcinoma; Translational Research; Underserved Population; Universities; Washington; Work; base; cancer biomarkers; cancer care; cancer diagnosis; cancer prevention; circulating biomarkers; health disparity; immune resistance; instrumentation; investigator-initiated trial; liquid crystal polymer; malignant breast neoplasm; meetings; member; minority health disparity; molecular oncology; nano-string; next generation sequencing; optimal treatments; pembrolizumab; personalized immunotherapy; pre-clinical; pre-clinical research; precision medicine; precision oncology; predictive marker; programs; survivorship; trend; tumor microenvironment; tumor progression; underserved minority

ABSTRACT The overall mission of the Experimental Therapeutics Program (ET) is to reduce the burden of cancer through preclinical and early clinical drug development; determine optimal treatment combinations and sequences; identify prognostic, predictive and surrogate markers of efficacy and resistance for active agents and deliver best practices to our catchment area and nationally through strategic collaborations. ET encompasses a combination of preclinical, translational and clinical research, with strong ties to the other programs (Breast Cancer [BC], Cancer Prevention and Control [CPC] and Molecular Oncology [MO]). Given its clinical focus, ET has evolved in concert with recent trends and discoveries that have had an impact in the clinic, such as immunotherapy and precision medicine. Aim 1 is focused on targeting known driver pathways of cancer. Aim 2 is focused on targeting the tumor microenvironment (TME) and the immune system. Aim 3 is focused on developing drugs and biomarkers for cancer diagnosis, prognosis and therapy. Significant accomplishments include completing an investigator-initiated trial (IIT) demonstrating the efficacy of pembrolizumab in thymic carcinoma that is shifting the treatment paradigm and work demonstrating the molecular determinants of immune resistance that are identifying new targets for immunotherapy. ET is led by Giuseppe Giaccone, MD, PhD, former Chief of the National Cancer Institute (NCI) Oncology Branch and a leading expert in lung cancer and experimental therapeutics, and Anton Wellstein, MD, PhD, a pharmacologist whose translational research is focused on tumor stromal interactions and mechanisms of cancer progression to metastasis. The LCCC Consortium is comprised of Georgetown Comprehensive Cancer Center, based in Washington, DC (LCCC-DC) and the John Theurer Cancer Center of Hackensack Meridian Health, based in Hackensack, NJ (LCCC-NJ). Accordingly, the LCCC catchment area is defined by the LCCC-DC and LCCC-NJ catchment areas. ET has 43 members, including translational and clinical researchers, from six departments across the Lombardi Comprehensive Cancer Center (LCCC) consortium institutions. The program is funded by $17.81M ($15.84M LCCC-DC, $1.97M LCCC-NJ) in research funding (annual direct costs) of which $1.3M ($0.98M LCCC-DC, $0.32M LCCC-NJ) is peer-reviewed and $0.86M ($0.54M LCCC-DC, $0.32M LCCC-NJ) is NCI funded. ET members published 578 papers, of which 137 were high impact (impact factor [IF] ≥ 8); 15% interprogrammatic, 23% intraprogrammatic and 48% involving external collaborations with other NCI-designated cancer centers. ET members use all nine LCCC Shared Resources. ET addresses challenges in LCCC’s catchment areas in Washington DC and surrounding counties (LCCC-DC) and Bergen County, New Jersey (LCCC-NJ) by focusing on diseases that are relatively overrepresented, such as pancreatic cancer and lung cancer, and offering research-inspired cancer care to patients, including underserved minorities, throughout these catchment areas.

抽象的 实验治疗计划（ET）的整体任务是通过 临床前和早期临床药物开发；确定最佳的治疗组合和序列； 确定活跃药物的效率和耐药性的预后，预测性和替代标志物，并提供最佳 通过战略合作到我们的集水区和全国的实践。 ET包括一个组合 临床前，翻译和临床研究，与其他计划有密切的联系（乳腺癌[BC]， 癌症预防和控制[CPC]和分子肿瘤学[MO]）。鉴于其临床重点，ET在 与最近在诊所产生影响的趋势和发现的音乐会，例如免疫疗法和 精密医学。 AIM 1专注于靶向已知的癌症驱动器途径。 AIM 2专注于 靶向肿瘤微环境（TME）和免疫系统。 AIM 3专注于开发药物， 癌症诊断，预后和治疗的生物标志物。重大成就包括完成 研究者发射的试验（IIT）证明了pembrolizumab在胸腺癌中的效率 处理范式和工作证明了免疫抗性的分子决定剂 确定免疫疗法的新靶标。 ET由前总裁Giuseppe Giacone，医学博士领导 国家癌症研究所（NCI）肿瘤科，肺癌和实验专家 治疗和医学博士Anton Wellstein，一名药物，其转化研究的重点是肿瘤 癌症发展到转移的基质相互作用和机制。 LCCC财团已完成 位于华盛顿特区（LCCC-DC）的乔治敦综合癌症中心和约翰·塞雷尔（John Theurer） Hackensack Meridian Health的癌症中心，总部位于新泽西州Hackensack（LCCC-NJ）。根据LCCC 集水区由LCCC-DC和LCCC-NJ集水区定义。 ET有43位成员，包括 伦巴第综合癌症中心的六个部门的翻译和临床研究人员 （LCCC）财团机构。该计划由1.781亿美元（1,584万美元的LCCC-DC，197万美元的LCCC-NJ）资助 研究资金（年度直接费用），其中130万美元（$ 98万LCCC-DC，32万美元的LCCC-NJ）正在同行评审 NCI资助了86万美元（5400万美元的LCCC-DC，33万美元的LCCC-NJ）。 ET成员发表了578篇论文，其中 137是高影响力（影响因子[如果]≥8）； 15％的解释性截图，23％的术中和48％涉及 与其他NCI指定的癌症中心的外部合作。 ET成员使用共享的所有九个LCCC 资源。 ET解决了华盛顿特区及周边县LCCC集水区的挑战 （LCCC-DC）和新泽西州卑尔根县（LCCC-NJ），专注于相对疾病 胰腺癌和肺癌等过多的代表性，并提供研究灵感的癌症护理 在这些集水区中，包括服务不足的少数民族在内的患者。